Overview

Long Term Efficacy and Safety of Inhaled Colistimethate Sodium in Bronchiectasis Subjects With Chronic Pseudomonas Aeruginosa Infection.

Status:
Completed

Trial end date:
2021-04-09

Target enrollment:

Participant gender:

Summary

The primary objective of the trial is to investigate the effect of the use of inhaled colistimethate sodium, administered twice daily via the I-neb for 12 months, compared to placebo in subjects with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with P. aeruginosa on the frequency of pulmonary exacerbations.

Phase:

Phase 3

Details

Lead Sponsor:

Zambon SpA

Treatments:

Colistin
Pharmaceutical Solutions